| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2020: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
Gastric cancer (GC) is generally sub-classified into "intestinal type" that expresses MUC2 or CD10 and "gastric type" that expresses MUC5AC or MUC6 based on the immunohistochemical analysis. It is well known that both intestinal and gastric type cancers are underpinned by different genetic and molecular background.
We generated a GC organoid library that is composed of 50 GC cases, including the results of several IHC staining, MSI and mutation status. We also examined the drug sensitivity against representative anti-cancer drugs.
We then performed RNA sequence using GC organoids with intestinal and gastric types, and found out several candidate genes that are involved in the resistance against 5-FU and oxaliplatin. Currently, several studies that aim to reveal molecular machinery concerning attainment of drug resistance are ongoing. We are also conducting a screening of the specific inhibitors against above-mentioned candidates in collaboration with a pharmatheutic company.
|
